GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.

Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

Experts say no inhaler suits every patient with chronic obstructive pulmonary disease, and technique can fade within 30 days without retraining.

Experts say COPD care should aim for disease stability, with advanced therapy a routine next step, not a last resort, for patients who fall short.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.